"Docs4PatientCare.org is a politically neutral grassroots coalition of physicians. Use of any politically partisan terms does not reflect the position of Docs4PatientCare.org. We do encourage our speakers to express how they feel and we post articles based on their informative content only. Any politically partisan language used does not reflect the group as a whole. Specific party or political allegiances and opposition are not our intent. The goal of D4PC is only to advocate for effective and responsible health care reform."
According to PharmaTimes Online, Britain's National Institutes of Health are denying lupus patients access to the first new drug for this disease in 50 years. PharmaTimes reports NIH "concluded that Benlysta (belimumab) could not be considered a cost-effective use of NHS resources for patients with active autoantibody positive systemic lupus erythematosus with a high degree of disease activity despite standard therapy."
Simon Jose, General Manager at GlaxoSmithKline the company that developed the drug, has been highly critical of the decision for its failure to recognize and adopt innovative new medicines stating, "The appraisal system itself, and its failure to recognise innovation, remains a fundamental problem" and that the UK is "one of the slowest to enable patients to have access to innovative new treatments."
When government bureaucrats, and not patients in consultation with their doctors, have the power to make the kind of health care decisions that affect patients, patients are ultimately denied access to care. That is why D4PC is fighting so hard to repeal ObamaCare - to protect our patients health.
Read more about this issue here.